---
title: "Imlifidase in Kidney transplantation in highly sensitized patients: Clinical evidence"
description: "Formulary evidence on Imlifidase in Kidney transplantation in highly sensitized patients: Clinical evidence. Covers ConfIdeS, Highdes, 13-HMedIdeS-03, 14-HMedIdeS-04, 20-HMedIdeS-19, 17-HMedIdeS-14, and 11 further headings. 159 evidence topics quoted from 29 sources."
canonical: "https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imlifidase in Kidney transplantation in highly sensitized patients: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 ConfIdeS

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Kidney function objective

> “12-month kidney function”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Participating sites

> “25 U.S. sites”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### ConfIdeS, NCT04935177: design

> “pivotal Phase 3 open label, randomized, controlled trial”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="topic-3.1.1.3-2"></a>

###### Randomization ratio

> “1:1”

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Crossmatch eligibility

> “positive crossmatch against a deceased donor”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### ConfIdeS, NCT04935177: control-arm treatments

> “any combination of PLEX, IVIG, anti-CD20, eculizumab, or waiting a more compatible organ”

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="topic-3.1.1.5-2"></a>

###### Immunosuppression in the imlifidase arm

> “rabbit anti-thymocyte globulin induction”
> “corticosteroids, mycophenolic acid, and tacrolimus”

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Estimated Glomerular Filtration Rate at 12 Months as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint

> “eGFR at 12 months”

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="topic-3.1.1.6.1-2"></a>

###### Validation of the primary endpoint as a surrogate for long-term clinical benefit

No evidence found.

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### ConfIdeS, NCT04935177: randomized population

> “64 highly sensitized (cPRA ≥99.9%)”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Timing of transplantation

| Disposition | Participants |
| --- | --- |
| Imlifidase arm: transplanted at randomization | “28” |
| Control arm: transplanted at randomization | “3” |
| Control arm: additional later transplants | “12” |

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### ConfIdeS, NCT04935177: primary endpoint results

> “At 12 months, mean eGFR was 51.5 mL/min/1.73m[2] in the imlifidase arm versus 19.3 mL/min/1.73m[2] in the control arm”
> “p<0.0001”

Source: [Hansa Biopharma ConfIdeS primary endpoint announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/)

<a id="topic-3.1.1.8.3-2"></a>

###### ConfIdeS, NCT04935177: dialysis dependence

> “Dialysis dependence was greater in the control arm (56% vs 16%; p=0.0007).”

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### ConfIdeS, NCT04935177: antibody-mediated rejection

> “16/28 patients in the imlifidase arm (57%)”
> “6/13 in the control arm (46%)”

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Treatment-emergent adverse events and patient survival

| Outcome | Quoted result |
| --- | --- |
| Treatment-emergent adverse events, total events | “386” |
| Patient survival: imlifidase | “97%” |
| Patient survival: control | “100%” |

Source: [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

ConfIdeS randomized 64 participants but was open label, and its control arm allowed several desensitization approaches or continued waiting. The comparison therefore does not isolate imlifidase against one standardized active regimen. The rejection counts use denominators of 28 and 13 rather than the complete randomized population, so they should not be interpreted as randomized-population rejection risks. The reported primary comparison concerns kidney function at 12 months, not a demonstrated long-term survival benefit.

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/); [Kapturczak et al. (2026)](https://app.tts2026.org/program_view/lecture?id=765); [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf); [Hansa Biopharma ConfIdeS primary endpoint announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/)

<a id="heading-3.1.2"></a>

#### 3.1.2 Highdes

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Desensitization objective

> “converting a positive crossmatch test to negative”

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Recruitment start and participating countries

| Study characteristic | Quoted record |
| --- | --- |
| Recruitment start | “30 Sep 2016” |
| Participating country | “Sweden” |
| Participating country | “France” |
| Participating country | “United States” |

Source: [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Study design

> “open-label, single-arm, phase 2”

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Transplant donor eligibility

> “a living or deceased donor kidney”

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dosing groups

| Regimen | Dose |
| --- | --- |
| Single intravenous infusion | “0.25 mg/kg” |
| Two intravenous infusions | “2 x 0.25 mg/kg” |

Source: [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Crossmatch Conversion Within 24 Hours as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Crossmatch conversion and access to transplantation

> “allowing highly sensitized patients to be transplanted”

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Screened and enrolled populations

| Population | Participants |
| --- | --- |
| Screened | “21” |
| Enrolled | “19” |

Source: [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Registry analysis populations and statistical approach

| Analysis | Quoted record |
| --- | --- |
| Primary efficacy analysis set | “Full analysis” |
| Primary endpoint analysis population | “19” |
| Endpoint summaries | “descriptive statistics” |

Source: [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Completion by dosing group

| Disposition | One infusion | Two infusions |
| --- | --- | --- |
| Started | “16” | “3” |
| Completed | “13” | “3” |

Source: [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Median sensitization

| Baseline characteristic | Quoted value |
| --- | --- |
| Median calculated panel-reactive antibody | “99.83%” |

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Highdes, NCT02790437: crossmatch conversion

> “89.5% demonstrated conversion of baseline positive crossmatch to negative within 24 h”

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="topic-3.1.2.8.3-2"></a>

###### Long-term follow-up: survival

> “At 5 y, 7 of 8 participants were alive.”

Source: [Jaffe et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11723687/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Highdes, NCT02790437: antibody-mediated rejection

> “38.9% had early biopsy proven antibody-mediated rejection”

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/)

<a id="topic-3.1.2.8.5-2"></a>

###### Long-term follow-up: antibody-mediated rejection

> “No new episodes of suspected or biopsy-proven AMR occurred after 30 d posttransplant.”

Source: [Jaffe et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11723687/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

Highdes enrolled 19 participants without a randomized control group. Its primary endpoint was crossmatch conversion, which enables transplantation but does not alone establish long-term graft survival or freedom from rejection. The five-year single-site report concerns 8 participants from the same trial, not an additional independent trial population.

Source: [Jordan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8294837/); [EU Clinical Trials Register 2016-002064-13](https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002064-13/results); [Jaffe et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11723687/)

<a id="heading-3.1.3"></a>

#### 3.1.3 13-HMedIdeS-03

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary study objective

> “safety and tolerability”

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Country and recruitment start

| Study characteristic | Quoted record |
| --- | --- |
| Country | “Sweden” |
| Recruitment start | “04 Jun 2015” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Masking

> “Not blinded”

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Intravenous dose groups

| Group | Dose |
| --- | --- |
| First dose group | “0.25 mg/kg” |
| Second dose group | “0.50 mg/kg” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Safety Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Enrollment

| Population | Participants |
| --- | --- |
| Screened | “12” |
| Enrolled | “10” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Statistical approach

> “descriptive statistics”

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Study completion

| Disposition | First dose group | Second dose group |
| --- | --- | --- |
| Completed | “5” | “5” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Sex distribution

| Characteristic | Participants |
| --- | --- |
| Female | “7” |
| Male | “3” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### HLA antibody levels acceptable for transplantation within 24 hours

| Outcome | First dose group | Second dose group |
| --- | --- | --- |
| Participants meeting the endpoint | “5” | “5” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Adverse events through the study follow-up period

| Outcome | First dose group | Second dose group |
| --- | --- | --- |
| Adverse events, total events | “52” | “54” |

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

This unblinded study enrolled 10 participants in two dose groups of 5 and used descriptive analyses. It does not provide a randomized estimate of treatment effect. Its 52 and 54 adverse-event counts are numbers of events, not numbers of affected participants. The combined early-trial publication should not be added to this enrollment count as an independent population.

Source: [EU Clinical Trials Register 2014-000712-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000712-34/results); [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)

<a id="heading-3.1.4"></a>

#### 3.1.4 14-HMedIdeS-04

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Protocol objective

> “eliminating DSAs”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study institution

> “Cedars-Sinai Medical Center”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Protocol study design

> “open label exploratory study”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Age eligibility

> “Age 18-70 years”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Protocol imlifidase dose

> “0.24mg/kg”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="topic-3.1.4.5-2"></a>

###### Post-transplant immunosuppression in the combined publication

> “tacrolimus, mycophenolate mofetil, and glucocorticoids”

Source: [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Allograft Rejection as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Protocol outcome

> “incidence of allograft rejection”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="topic-3.1.4.6.1-2"></a>

###### Endpoint-specific validation

No evidence found.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Protocol planned enrollment

| Population | Participants |
| --- | --- |
| Planned | “20” |

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Sponsor-reported enrollment for NCT02426684

| Population | Participants |
| --- | --- |
| Enrolled | “17” |

Source: [Hansa Medical (2018)](https://www.hansabiopharma.com/media/press-releases/2018/the-american-journal-of-transplantation-publishes-results-from-hansa-medicals-first-phase-ii-study-with-ides/)

<a id="topic-3.1.4.7.1-3"></a>

###### United States participants in the combined publication

| Population | Participants |
| --- | --- |
| United States subgroup in the earlier publication | “14” |

Source: [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Protocol statistical limitation

> “not powered for efficacy end points”

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### HLA-incompatible transplantation: pooled donor-specific antibody reduction across the early studies

> “IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients.”

Source: [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Combined early-trial safety results: pooled, not specific to the United States study

| Outcome | Quoted count |
| --- | --- |
| Serious adverse events | “38” |
| Participants with serious adverse events | “15” |
| Events adjudicated as possibly related to IdeS | “5” |
| Participants with antibody-mediated rejection across both countries | “10” |
| United States participants with antibody-mediated rejection | “7” |

Source: [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The protocol describes an exploratory open-label study that was not powered for efficacy endpoints. Planned enrollment was 20 participants, and the later sponsor update reported 17. The earlier combined publication included 14 United States participants and reported several outcomes across 25 participants from both countries. Those pooled efficacy and safety counts must not be treated as outcomes for all 17 participants in this study alone.

Source: [Cedars-Sinai Medical Center study protocol (2016)](https://cdn.clinicaltrials.gov/large-docs/84/NCT02426684/Prot_SAP_001.pdf); [Hansa Medical (2018)](https://www.hansabiopharma.com/media/press-releases/2018/the-american-journal-of-transplantation-publishes-results-from-hansa-medicals-first-phase-ii-study-with-ides/); [Jordan et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28767349/)

<a id="heading-3.1.5"></a>

#### 3.1.5 20-HMedIdeS-19

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Post-authorization efficacy objective

> “one‑year graft failure‑free survival”

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Recruitment and geographic coverage

| Study characteristic | Quoted record |
| --- | --- |
| First participant enrolled | “May 2022” |
| Participating transplant centers | “22” |
| Participating countries | “11” |

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Reference-group design

> “Non-comparative concurrent”

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Recipient eligibility

| Criterion | Quoted value |
| --- | --- |
| Recipient age range, years | “18-75” |
| Sensitization threshold | “≥95%” |

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Pretreatment before transplantation

> “Idefirix pre‑treatment”

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Graft Failure-free Survival at One Year as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary endpoint result

> “The 1-year graft failure-free survival was 90%”

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="topic-3.1.5.6.1-2"></a>

###### Validation against a randomized comparator

No evidence found.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### European post-authorization efficacy study: enrollment

> “A total of 51 patients were enrolled”

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Analysis sets in the sponsor presentation

| Population | Imlifidase | Concurrent reference |
| --- | --- | --- |
| Safety analysis set | “51 (100)” | “63 (100)” |
| Intention-to-treat analysis set | “50 (98.0)” | “63 (100)” |

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Trial completion in the sponsor presentation

| Disposition | Imlifidase | Concurrent reference |
| --- | --- | --- |
| Completed trial | “48 (94.1)” | “57 (90.5)” |

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Baseline age in the sponsor presentation

| Characteristic | Imlifidase | Concurrent reference |
| --- | --- | --- |
| Mean age, years | “50.1” | “55.6” |

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### European post-authorization efficacy study: one-year outcomes

> “The 1-year graft failure-free survival was 90%”
> “graft survival was 92%, and patient survival was 98%.”

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="topic-3.1.5.8.3-2"></a>

###### One-year kidney function in the results announcement

| Outcome | Quoted value |
| --- | --- |
| Mean eGFR, mL/min/1.73 m² | “52.4” |

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Serious treatment-emergent adverse events in the sponsor presentation

| Population | Participants |
| --- | --- |
| Imlifidase safety population with serious treatment-emergent adverse events | “28 (54.9)” |

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The presentation distinguishes a safety population of 51 imlifidase-treated participants from an intention-to-treat population of 50. Its concurrent reference cohort is explicitly non-comparative, so the reported outcomes do not constitute a randomized comparative-effectiveness estimate. Forty-eight imlifidase-treated participants completed the trial. The one-year results do not resolve longer-term graft outcomes.

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/); [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="heading-3.1.6"></a>

#### 3.1.6 17-HMedIdeS-14

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Follow-up outcomes

> “Patient survival, graft survival, renal function”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Parent-trial treatment period

> “2014-2017”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Follow-up design

> “non-interventional”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Analysis eligibility

> “a positive crossmatch (+XM)”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

No evidence found.

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Long-term Graft Survival as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Kidney function assessment

> “local serum creatinine measurements”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="topic-3.1.6.6.1-2"></a>

###### Surrogate endpoint justification for survival outcomes

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Five-year follow-up extension, NCT03611621: population

> “39 patients”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Survival analysis

> “Kaplan-Meier methodology”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Five-year assessment population

| Population | Participants |
| --- | --- |
| Functioning grafts with reported five-year eGFR | “24” |

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Baseline sensitization

| Characteristic | Quoted value |
| --- | --- |
| Median cPRA | “99.62%” |

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Five-year follow-up extension, NCT03611621: patient and graft survival

> “Five-year patient survival was 90%”
> “Death-censored graft survival was 82%”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="topic-3.1.6.8.3-2"></a>

###### Five-year estimated glomerular filtration rate among functioning grafts

| Estimation method | Mean eGFR, mL/min/1.73 m² |
| --- | --- |
| Modification of Diet in Renal Disease | “50.1” |
| Chronic Kidney Disease Epidemiology Collaboration, 2021 | “55.8” |
| Third reported estimation equation, 2023 | “52.5” |

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Five-year follow-up extension, NCT03611621: late antibody-mediated rejection

> “No AMR occurred between 3 and 5 years.”

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

This non-interventional follow-up analysis includes 39 crossmatch-positive participants from earlier trials. It is not a new randomized treatment comparison. Five-year kidney-function estimates were available for 24 functioning grafts, so these estimates are conditional on graft function and available follow-up rather than representing all original participants. The three-year, five-year, and correspondence publications concern overlapping follow-up evidence and should not be counted as separate trial populations.

Source: [Lorant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697064/); [Kjellman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9290474/); [Jordan et al. (2025a)](https://www.amjtransplant.org/article/S1600-6135%2824%2900742-1/fulltext)

Additional sources: [Schinstock et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40373881/); [Jordan (2025b)](https://pubmed.ncbi.nlm.nih.gov/40451389/)

<a id="heading-3.1.7"></a>

#### 3.1.7 High-strength donor-specific antibody single-center cohort

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Transplantation objective

> “successful transplantation”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

No evidence found.

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Single-center experience

> “single-center's experience”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Crossmatch status

> “positive crossmatches”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Timing of IdeS administration

> “within 24 hours prior to transplant”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Crossmatch Conversion as the Primary Endpoint

Not applicable.

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Reported cohort

| Population | Participants |
| --- | --- |
| Transplant candidates | “7” |

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Baseline sensitization and donor type

| Characteristic | Quoted value |
| --- | --- |
| Calculated panel-reactive antibody range | “cPRA98-100%” |
| Deceased donors | “5” |
| Living donors | “2” |

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### High-strength donor-specific antibody: allograft function

> “All patients have functioning renal allografts at a median follow-up of 235 days.”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### High-strength donor-specific antibody: DSA rebound and rejection

> “Three patients had DSA rebound and antibody-mediated rejection”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="topic-3.1.7.8.5-2"></a>

###### Serious adverse events attributed to IdeS

> “No serious adverse events were associated with IdeS.”

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

This single-center report describes 7 participants, including 5 deceased-donor and 2 living-donor transplant recipients. All had functioning grafts at a median follow-up of 235 days, but 3 experienced antibody rebound and antibody-mediated rejection. The small series does not provide a randomized comparator. Its participants should not be assumed to be independent of other trial or follow-up publications without confirmation of participant overlap.

Source: [Lonze et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30004918/)

<a id="heading-3.1.8"></a>

#### 3.1.8 Positive-crossmatch deceased-donor real-world cohort

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Clinical-practice study objective

> “short-term efficacy and safety”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Minimum observation period

> “at least 3 months of follow-up”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Initial clinical-practice cohort

> “the first 9 patients”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Crossmatch eligibility

> “positive crossmatch”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Imlifidase exposure

> “After 1 injection of imlifidase, all were negative.”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Crossmatch Conversion as the Primary Endpoint

Not applicable.

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Reported cohort size

| Population | Participants |
| --- | --- |
| Transplanted cohort | “9” |

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Baseline calculated panel-reactive antibody

| Characteristic | Quoted value |
| --- | --- |
| Lower reported sensitization category | “99%” |
| Higher reported sensitization category | “100%” |

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Positive crossmatch against a deceased donor: crossmatch conversion

> “After 1 injection of imlifidase, all were negative.”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="topic-3.1.8.8.3-2"></a>

###### Kidney function and observation period

| Outcome | Quoted value |
| --- | --- |
| Mean eGFR at last follow-up, mL/min/1.73 m² | “56 ± 22” |
| Mean follow-up, months | “7 ± 2.8” |

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Positive crossmatch against a deceased donor: graft loss, death, and infections

> “No graft loss or death were observed. Four patients developed at least 1 infection.”

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

This clinical-practice cohort comprised 9 transplanted participants with at least 3 months of follow-up. The mean reported follow-up was 7 months. Crossmatch conversion occurred after one imlifidase injection, but 4 participants developed at least one infection. The small cohort and short follow-up do not establish comparative effectiveness or long-term graft survival.

Source: [Kamar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11489446/)

<a id="heading-3.1.9"></a>

#### 3.1.9 DINKY

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Pediatric treatment objective

> “enable transplantation”

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Planned United Kingdom site

> “Great Ormond Street Hospital”

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Planned design

> “single-arm, multi-centre”

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Age eligibility

> “1-17 years”

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Timing of imlifidase treatment

> “before a kidney transplantation”

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Crossmatch Conversion as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

###### Crossmatch conversion rationale

> “change a positive crossmatch test to negative”

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Planned enrollment in the research summary

| Population | Participants |
| --- | --- |
| Planned | “10” |

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

The research summary describes a single-arm pediatric trial with planned enrollment of 10 participants aged 1 to 17 years. This design does not provide a randomized comparator. No study results are included in this report, so the planned study cannot establish pediatric efficacy or safety here.

Source: [Health Research Authority](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/desensitisation-with-imlifidase-prior-to-kidney-transplant-in-highly-sensitised-children-dinky/); [ClinicalTrials.gov NCT05753930](https://clinicaltrials.gov/study/NCT05753930)

<a id="heading-3.1.10"></a>

#### 3.1.10 Lupus nephritis retransplantation case report

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Immunoglobulin monitoring

> “Circulating immunoglobulins were monitored”

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

No evidence found.

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Study design

> “case report”

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Treatment before retransplantation

> “pre-treated with imlifidase”

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Donor-specific Antibody Reduction as the Primary Endpoint

Not applicable.

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Individual case

> “the case of a 51 years old woman”

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

###### Baseline features

| Characteristic | Quoted record |
| --- | --- |
| Underlying kidney disease | “lupus nephritis” |
| Sensitization | “cPRA>99 %” |

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Additional case reports

> “DSA rebound at recovery was absent and remained under the positivity threshold (MFI = 1000) after 6 months.”

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="topic-3.1.10.8.3-2"></a>

###### Maximum reported total IgG depletion at 36 hours

| Outcome | Quoted value |
| --- | --- |
| Total IgG reduction from baseline | “-75 %” |

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

No evidence found.

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

The report concerns one 51-year-old woman with lupus nephritis undergoing retransplantation. The absence of donor-specific antibody rebound at six months is an individual observation, not an estimate of response probability. The case does not establish comparative efficacy or safety in other highly sensitized transplant candidates.

Source: [Milhès et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755536/)

<a id="heading-3.1.11"></a>

#### 3.1.11 Desensitization with imlifidase case report

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

No evidence found.

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

No evidence found.

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

No evidence found.

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

No evidence found.

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Clinical Transplant Outcomes as the Primary Endpoint

Not applicable.

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

Additional sources: [Hernández-Velasco et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41050132/)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

No evidence found.

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

No evidence found.

<a id="heading-3.1.12"></a>

#### 3.1.12 Anti-MICA antibody case report

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

###### Antibody monitoring objective

> “dynamics of anti-MICA antibodies”

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

No evidence found.

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

###### Individual recipient report

> “a kidney transplant recipient”

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

###### Treatment used after rejection

> “immunoadsorption and daratumumab”

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Anti-MICA Antibody Reduction as the Primary Endpoint

Not applicable.

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

###### Reported participant

> “a kidney transplant recipient”

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

<a id="topic-3.1.12.8.2-1"></a>

###### Baseline donor-specific antibodies

> “anti-MICA*002 preformed DSA”

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

###### Antibody rebound and subsequent removal

| Outcome | Quoted timing |
| --- | --- |
| Anti-MICA donor-specific antibody rebound after imlifidase | “14 days” |
| Removal of anti-MICA antibodies after subsequent treatment | “day 45” |

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

<a id="topic-3.1.12.8.5-1"></a>

###### Rejection event

> “early antibody-mediated rejection”

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

This report describes one recipient with preformed anti-MICA donor-specific antibodies. Antibody rebound occurred after 14 days, and early antibody-mediated rejection was reported. Later antibody removal followed immunoadsorption and daratumumab, so that outcome cannot be attributed to imlifidase alone.

Source: [Beaudrey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826255/)

<a id="heading-3.1.13"></a>

#### 3.1.13 Molecular diagnosis of early alloimmune injury case report

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

No evidence found.

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

No evidence found.

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

No evidence found.

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

No evidence found.

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Molecular Assessment of Alloimmune Injury as the Primary Endpoint

Not applicable.

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

Additional sources: [Hamdini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42592609/)

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

No evidence found.

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

No evidence found.

<a id="heading-3.1.14"></a>

#### 3.1.14 Pediatric compassionate-use case report

<a id="heading-3.1.14.1"></a>

##### 3.1.14.1 Objective

No evidence found.

<a id="heading-3.1.14.2"></a>

##### 3.1.14.2 Location and Study Date

No evidence found.

<a id="heading-3.1.14.3"></a>

##### 3.1.14.3 Study Design

No evidence found.

<a id="heading-3.1.14.4"></a>

##### 3.1.14.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.14.5"></a>

##### 3.1.14.5 Treatment

No evidence found.

<a id="heading-3.1.14.6"></a>

##### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

###### 3.1.14.6.1 Rationale for Using Clinical Transplant Outcomes as the Primary Endpoint

Not applicable.

<a id="heading-3.1.14.7"></a>

##### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

###### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.14.7.2"></a>

###### 3.1.14.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.14.8"></a>

##### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

###### 3.1.14.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.14.8.2"></a>

###### 3.1.14.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.14.8.3"></a>

###### 3.1.14.8.3 Efficacy Results

Additional sources: [Houp and Seifert (2025)](https://www.amjtransplant.org/article/S1600-6135%2825%2902388-3/fulltext)

<a id="heading-3.1.14.8.4"></a>

###### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.14.8.5"></a>

###### 3.1.14.8.5 Safety Results

No evidence found.

<a id="heading-3.1.14.9"></a>

##### 3.1.14.9 Study Limitations

No evidence found.

<a id="heading-3.1.15"></a>

#### 3.1.15 NCT03897205

<a id="heading-3.1.15.1"></a>

##### 3.1.15.1 Objective

<a id="topic-3.1.15.1-1"></a>

###### Trial indication

> “ABMR indication”

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.2"></a>

##### 3.1.15.2 Location and Study Date

<a id="topic-3.1.15.2-1"></a>

###### Multinational trial sites

| Characteristic | Quoted count |
| --- | --- |
| Transplant centers | “14” |

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.3"></a>

##### 3.1.15.3 Study Design

<a id="topic-3.1.15.3-1"></a>

###### Trial design

> “randomized, open-label, multicenter, multinational”

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.4"></a>

##### 3.1.15.4 Eligibility Criteria

<a id="topic-3.1.15.4-1"></a>

###### Study population

> “kidney transplant recipients with ABMR”

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.5"></a>

##### 3.1.15.5 Treatment

<a id="topic-3.1.15.5-1"></a>

###### Randomized treatments

| Arm | Quoted treatment |
| --- | --- |
| Enzyme therapy | “imlifidase” |
| Active comparator | “PLEX” |

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.6"></a>

##### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

###### 3.1.15.6.1 Rationale for Using Donor-specific Antibody Reduction Within Five Days as the Primary Endpoint

<a id="topic-3.1.15.6.1-1"></a>

###### Biomarker endpoint and clinical benefit

> “the trial was unsuccessful in demonstrating a clinical benefit of imlifidase in this heterogenous ABMR population.”

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.7"></a>

##### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

###### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.15.7.1-1"></a>

###### Randomized population

| Population | Participants |
| --- | --- |
| Randomized | “Thirty” |

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.7.2"></a>

###### 3.1.15.7.2 Description of Analysis Sets

<a id="topic-3.1.15.7.2-1"></a>

###### Primary-endpoint analysis model

> “analysis of variance model”

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.8"></a>

##### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

###### 3.1.15.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.15.8.2"></a>

###### 3.1.15.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.15.8.3"></a>

###### 3.1.15.8.3 Efficacy Results

<a id="topic-3.1.15.8.3-1"></a>

###### Maximum donor-specific antibody reduction

| Outcome | Imlifidase | PLEX |
| --- | --- | --- |
| Primary-endpoint reduction | “97%” | “42%” |

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="topic-3.1.15.8.3-2"></a>

###### Post-transplant antibody-mediated rejection treatment, not pretransplant desensitization

> “the trial was unsuccessful in demonstrating a clinical benefit of imlifidase in this heterogenous ABMR population.”

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.8.4"></a>

###### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.15.8.5"></a>

###### 3.1.15.8.5 Safety Results

<a id="topic-3.1.15.8.5-1"></a>

###### Graft losses within six months

| Outcome | Imlifidase | PLEX |
| --- | --- | --- |
| Allograft losses | “four” | “one” |

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.15.9"></a>

##### 3.1.15.9 Study Limitations

<a id="topic-3.1.15.9-1"></a>

###### Summary

This randomized study addressed treatment of established antibody-mediated rejection after transplantation, not pretransplant desensitization. Thirty participants were randomized, and the trial was open label. Greater donor-specific antibody reduction with imlifidase did not establish clinical benefit; four graft losses occurred in the imlifidase arm and one in the plasma-exchange arm. These findings should not be pooled as direct evidence for the pretransplant indication.

Source: [Halleck et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.15383)

<a id="heading-3.1.16"></a>

#### 3.1.16 13-HMedIdeS-02

<a id="heading-3.1.16.1"></a>

##### 3.1.16.1 Objective

<a id="topic-3.1.16.1-1"></a>

###### Study objectives

> “Safety, immunogenicity, pharmacokinetics, and efficacy”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.2"></a>

##### 3.1.16.2 Location and Study Date

No evidence found.

<a id="heading-3.1.16.3"></a>

##### 3.1.16.3 Study Design

<a id="topic-3.1.16.3-1"></a>

###### Dose-escalation design

> “single-center, open-label ascending-dose study”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.4"></a>

##### 3.1.16.4 Eligibility Criteria

<a id="topic-3.1.16.4-1"></a>

###### Kidney disease population

> “chronic kidney disease”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.5"></a>

##### 3.1.16.5 Treatment

<a id="topic-3.1.16.5-1"></a>

###### Dose levels

| Dose level | Quoted dose |
| --- | --- |
| Lower dose per infusion | “0.12 mg/kg” |
| Higher dose per infusion | “0.25 mg/kg” |

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.6"></a>

##### 3.1.16.6 Study Outcomes

<a id="heading-3.1.16.6.1"></a>

###### 3.1.16.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

Not applicable.

<a id="heading-3.1.16.7"></a>

##### 3.1.16.7 Statistical Analysis Description

<a id="heading-3.1.16.7.1"></a>

###### 3.1.16.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.16.7.1-1"></a>

###### Enrolled population

| Population | Participants |
| --- | --- |
| Enrolled | “Eight patients with cytotoxic PRAs (median cytotoxic PRAs of 64%) at enrollment received 1 or 2 intravenous infusions of IdeS on consecutive days” |

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.7.2"></a>

###### 3.1.16.7.2 Description of Analysis Sets

<a id="topic-3.1.16.7.2-1"></a>

###### Pharmacokinetic model

> “Pharmacokinetics was evaluated using an open 2‐compartment model.”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.8"></a>

##### 3.1.16.8 Results

<a id="heading-3.1.16.8.1"></a>

###### 3.1.16.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.16.8.2"></a>

###### 3.1.16.8.2 Baseline Characteristics

<a id="topic-3.1.16.8.2-1"></a>

###### Baseline sensitization

| Characteristic | Quoted value |
| --- | --- |
| Median cytotoxic panel-reactive antibody | “64%” |

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.8.3"></a>

###### 3.1.16.8.3 Efficacy Results

<a id="topic-3.1.16.8.3-1"></a>

###### Pharmacodynamics: NCT02224820

> “<1% plasma IgG remaining within 48 hours”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.8.4"></a>

###### 3.1.16.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.16.8.5"></a>

###### 3.1.16.8.5 Safety Results

<a id="topic-3.1.16.8.5-1"></a>

###### Immunogenicity: NCT02224820

> “Anti-IdeS antibodies developed 1 week after treatment, peaking at 2 weeks.”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.16.9"></a>

##### 3.1.16.9 Study Limitations

<a id="topic-3.1.16.9-1"></a>

###### Summary

This single-center, open-label ascending-dose study enrolled 8 participants with chronic kidney disease. It establishes pharmacodynamic and immunogenicity observations in a small population, not a randomized estimate of transplantation benefit or long-term safety. IgG depletion within 48 hours and anti-IdeS antibody development are distinct outcomes and should not be equated with sustained clinical benefit.

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="heading-3.1.17"></a>

#### 3.1.17 11-HMedIdeS-01

<a id="heading-3.1.17.1"></a>

##### 3.1.17.1 Objective

<a id="topic-3.1.17.1-1"></a>

###### First-in-human objective

> “safety and tolerability”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.2"></a>

##### 3.1.17.2 Location and Study Date

<a id="topic-3.1.17.2-1"></a>

###### Study location

> “Lund, Sweden”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.3"></a>

##### 3.1.17.3 Study Design

<a id="topic-3.1.17.3-1"></a>

###### Allocation and masking

> “double blinded and randomized”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.4"></a>

##### 3.1.17.4 Eligibility Criteria

<a id="topic-3.1.17.4-1"></a>

###### Healthy-volunteer population

> “healthy, male subjects”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.5"></a>

##### 3.1.17.5 Treatment

<a id="topic-3.1.17.5-1"></a>

###### Phase 1 study in healthy subjects: NCT01802697

> “Twenty healthy subjects were given intravenous single ascending doses of IdeS.”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.6"></a>

##### 3.1.17.6 Study Outcomes

<a id="heading-3.1.17.6.1"></a>

###### 3.1.17.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

Not applicable.

<a id="heading-3.1.17.7"></a>

##### 3.1.17.7 Statistical Analysis Description

<a id="heading-3.1.17.7.1"></a>

###### 3.1.17.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.17.7.1-1"></a>

###### Reported trial populations

| Population | Quoted count |
| --- | --- |
| Total participants | “29” |
| Placebo recipients | “nine” |

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.7.2"></a>

###### 3.1.17.7.2 Description of Analysis Sets

<a id="topic-3.1.17.7.2-1"></a>

###### Sample-size planning

> “No formal power calculations have been performed.”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.8"></a>

##### 3.1.17.8 Results

<a id="heading-3.1.17.8.1"></a>

###### 3.1.17.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.17.8.2"></a>

###### 3.1.17.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.17.8.3"></a>

###### 3.1.17.8.3 Efficacy Results

<a id="topic-3.1.17.8.3-1"></a>

###### Phase 1 pharmacodynamic response

> “IgG reached nadir 6-24 hours after dosing and then slowly recovered.”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.8.4"></a>

###### 3.1.17.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.17.8.5"></a>

###### 3.1.17.8.5 Safety Results

<a id="topic-3.1.17.8.5-1"></a>

###### Serious adverse events

> “no serious adverse events”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="heading-3.1.17.9"></a>

##### 3.1.17.9 Study Limitations

<a id="topic-3.1.17.9-1"></a>

###### Summary

The trial included 29 healthy male participants, with 20 receiving IdeS and 9 receiving placebo. No formal power calculation was performed. Although the study reported no serious adverse events, its small healthy-volunteer population does not establish safety or efficacy in highly sensitized kidney transplant candidates receiving concomitant immunosuppression.

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

## Related pages
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Terms and abbreviations](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations.md)
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Product information and disease description](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Economic information and modeling report](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: References](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: prevalence by geography](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses.md)
